Bücher der Reihe Falk Symposium

There is currently an explosive growth of basic and clinical research in inflammatory bowel diseases.

This volume is the proceedings of the symposium 'Trends in Inflammatory Bowel Disease Therapy 1999' held in Vancouver, Canada, August 27-29, 1999, and sponsored by the Canadian Association of Gastroenterology, The Crohn's and Colitis Foundation of Canada and Axcan Pharma. It is the seventh international IBD symposium to be held in Canada and focuses on all areas of IBD therapy.Topics include: genetics; pathogenesis with reference to the role of autoimmunity, bacterial factors and neutrophil -- epithelial interactions; special clinical problems such as difficult diagnoses and challenges presented by children and the elderly; bone disease in IBD; an overview of current therapy; and a discussion of alternative therapy.

Features the proceedings of Falk Symposium 133 on Mechanisms of Intestinal Inflammation: Implications for Therapeutic Intervention in IBD', held in Berlin, Germany, on 10-11 June 2003. This book is useful for scientists and physicians, who have an interest in research on IBD and in the clinical management of these diseases.

In recent years, our knowledge about the pathogenesis, pathophysiology and treatment of hepatobiliary diseases has increased considerably.

Symposium in Honour of Gustav Paumgartner

The Proceedings of Falk Symposium No. 116, held in Basel, Switzerland, October 25, 1999, (Part III of the Basel Liver Week 1999)

The therapeutic handling of autoimmune liver disease is limited because basic mechanistic insights into immunologically mediated pathophysiology have not yet been translated into standard pharmacological treatments.

It covers our present knowledge of the diagnosis, treatment and prevention of liver diseases, including hepatitis B, hepatitis C and delta hepatitis as well as alcoholic liver diseases, non-alcoholic steatohepatitis and the hereditary liver diseases haemochromatosis, Wilson's disease and alpha-1-antitrypsin deficiency.

Cancer chemotherapy frequently attacks the gastrointestinal tract. This book is the proceedings of the Falk Workshop 'Side-effects of Chemotherapy on the Gastrointestinal Tract: Pathogenesis and Therapy', held in Freiburg, Germany, on October 11, 2002 (Part IV of the Freiburg Gastroenterology Week).

Features the proceedings of Falk Symposium 130 on 'Gastrointestinal Inflammation and Disturbed Gut Function: The Challenge of New Concepts', held in Freiburg, Germany, on October 4-6, 2002. This book reviews work in the field and aims to stimulate research in the functional GI disorders.

Short chain fatty acids (SFCA) are synthesized by the colonic microflora primarily from non-absorbed carbohydrate;

The IXth International Congress on Liver Diseases brought together experts from around the world to give information on developments in this field which are important both for research and clinical work. This title contains proceedings that is suitable for researchers and clinicians dealing with effects of liver diseases on the entire organism.

This book contains the proceedings of the XIIIth International Bile Acid Meeting (Falk Symposium 80), an official satellite meeting of the World Congress of Gastroenterology, held in San Diego, California, U.S.A., September 30--October 2, 1994.

Bile Acids in Liver Diseases, the proceedings of an International Falk Workshop held in Munich, January 1995, provides insights into current concepts in bile acid chemistry, bile acid synthesis and metabolism, and transport of bile acids across the hepatocyte.

This book is the proceedings of a Falk Workshop held in Berlin, Germany, on January 23-24, 2003, which brought together experts in different fields of research to stimulate the transfer of findings from basic research to clinical application.

The development and clinical application of cell therapy for patients with liver disease could soon present a significant enhancement of the therapeutic options. Present concepts of cell therapy for liver diseases based on the use of primary hepatocytes have recently been considerably extended through new data on the biology of stem cells.

Liver cirrhosis is a major clinical problem worldwide and is associated with significant morbidity and mortality from its complications, such as liver cell insufficiency with coagulopathy and hepatic encephalopathy, portal hypertension with ascites and gastrointestinal bleeding, hepatorenal syndrome, HCC development and others.

Sections of this book, the Proceedings of the conference, are devoted to extraintestinal manifestations, cancer development, IBD in the context of pregnancy, and the assessment of disease activity, prognosis and quality of life.

Cytokines are synthesized and secreted in the liver by Kupffer cells, and are important for inflammation processes, the non-specific immune response, and probably the destruction and removal of tumour cells.

During the last decade, knowledge about cholestatic liver disease and concomitant diseases, such as ulcerative colitis, cholangio- and hepatocellular carcinoma, pancreas and colon cancer, has increased considerably.

This book, the proceedings of a Falk Workshop on `Topical Steroids in Gastroenterology and Hepatology', held in Berlin, Germany, on 14 June 2003, critically discusses the current role of budesonide in gastroenterology, hepatology, surgery and oncology and focuses especially on potential new indications for the use of budesonide.

Development and progression of gastrointestinal disease involves inflammatory, vascular, fibrogenetic and immune reactions accompanied by deregulation of cellular growth and death often resulting in cancer of the organs affected.

There has been a tremendous amount of scientific progress in our understanding of the molecular mechanisms of transport processes in the liver within the last few years.

Concerning the therapy of autoimmune liver diseases, corticosteroids and azathioprin remain the state of the art for autoimmune hepatitis, while bile acids have become well established in treatment of primary biliary cirrhosis as well as primary sclerosing cholangitis.

The proceedings of the workshop not only discusses this, but moves on to examine its possible use in alcoholic liver disease, and moves back to re-examine its role in biliary disease.

These proceedings of Falk Symposium 110 on `Intestinal Mucosa and its Diseases - Pathophysiology and Clinics' held at Titisee/Black Forest, Germany, 16-17 October 1998, comprehensively review salient clinical as well as scientific aspects - pending or settled - of the main intestinal diseases.

135 held in Prague, Czech Republic, on September 12-13, 2003, and is dedicated to the important issue of immunological aspects of diseases of the liver and gut. Without any doubt, immunological pathways are among the most important and universal factors in the pathogenesis of all diseases.

Although the first description of patients with what we now call Crohn's disease or ulcerative colitis was published well before 1900, both disorders seem to be diseases of the twentieth century.

Knowledge about the cell biology of the cholangiocytes and the function of the bile ducts has increased considerably. Their role in liver diseases is increasingly recognized. This work brings together scientists and clinicians to highlight the advances in molecular biology, physiology, diagnosis and therapy of diseases of the biliary system.

Pregnancy is the main determinant of some liver diseases in humans: acute fatty liver of pregnancy, cholestasis of pregnancy, and acute liver failure in toxaemia of pregnancy.